Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 28, 2009

Premium

Carl Hull has been elected to the board of directors of the CHI-California Healthcare Institute, a non-profit public policy research organization that represents California academic institutions, biotechnology, medical device, diagnostics, and pharmaceutical firms.

Hull is currently president and CEO of Gen-Probe. Previously, he was vice president and general manager of the SDS/arrays business unit of Applied Biosystems. Prior to that, he held a number of positions, including that of CEO, with Applied Imaging. Hull holds a master's degree in business administration from the University of Chicago and a bachelor's degree in political science and international relations from Johns Hopkins University.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.